New and Emerging Therapies for Pulmonary Complications of Cystic Fibrosis

Overview

Journal Drugs

Specialty Pharmacology

Date 2001 Sep 18

PMID 11558827

Citations 1

Authors

M R Tonelli

M L Aitken

Affiliations

Soon will be listed here.

Abstract

In the decade since the gene for cystic fibrosis (CF) was discovered, research into potential therapeutic interventions has progressed on a number of different fronts. The vast majority of morbidity and mortality in CF results from inflammation and infection of the airways. Direct delivery of antibacterials to the airway secretions via a nebuliser is an attractive therapeutic option, and a novel formulation of tobramycin designed for such a purpose has been demonstrated to improve spirometry and decrease the need for intravenous antibacterials. In addition, early clinical trials are studying the effects of small peptides with antibiotic properties (defensins) delivered directly to the airways. Inflammation, whether secondary to infection or an independent feature of CF, leads to progressive bronchiectasis. Anti-inflammatories such as prednisone and possibly ibuprofen have been shown to decrease the rate of respiratory decline in patients with CF but have tolerability profiles that limit clinical usefulness. Macrolides also have anti-inflammatory properties and clinical trials are now ongoing to assess the efficacy of these agents in CF. Multiple agents, including uridine triphosphate (UTP), genistein, phenylbutyrate and CPX (cyclopentyl dipropylxanthine), have been demonstrated in cell culture to at least partially correct the primary defect of ion transport related to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). No agent of this class has yet demonstrated clinical effectiveness, but several are in preclinical and early clinical trials. Finally, gene therapy that allows for the incorporation and expression of wild-type CFTR in respiratory epithelial cells would be definitive therapy for CF. However, multiple barriers to delivery and expression need to be overcome. With research proceeding on these multiple fronts, new therapies for pulmonary complications promise to continue to increase the life expectancy of individuals with CF.

Citing Articles

Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Cheer S, Waugh J, Noble S Drugs. 2003; 63(22):2501-20.

PMID: 14609360 DOI: 10.2165/00003495-200363220-00015.

References

Pryor J, Webber B, Hodson M, Warner J . The Flutter VRP1 as an adjunct to chest physiotherapy in cystic fibrosis. Respir Med. 1994; 88(9):677-81. DOI: 10.1016/s0954-6111(05)80066-6. View

King M, Dasgupta B, Tomkiewicz R, Brown N . Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med. 1997; 156(1):173-7. DOI: 10.1164/ajrccm.156.1.9512074. View

Dezateux C, Walters S, Balfour-Lynn I . Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2000; (2):CD001915. DOI: 10.1002/14651858.CD001915. View

Bauldoff G, Nunley D, Manzetti J, Dauber J, Keenan R . Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation. 1997; 64(5):748-52. DOI: 10.1097/00007890-199709150-00015. View

Arens R, Gozal D, Omlin K, Vega J, Boyd K, Keens T . Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1994; 150(4):1154-7. DOI: 10.1164/ajrccm.150.4.7921452. View

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

Gill D, Southern K, Mofford K, Seddon T, Huang L, Sorgi F . A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997; 4(3):199-209. DOI: 10.1038/sj.gt.3300391. View

Albelda S, Wiewrodt R, Zuckerman J . Gene therapy for lung disease: hype or hope?. Ann Intern Med. 2000; 132(8):649-60. DOI: 10.7326/0003-4819-132-8-200004180-00008. View

Rosenstein B, Eigen H . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics. 1991; 87(2):245-6. View

10.

Smith J, Travis S, Greenberg E, Welsh M . Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996; 85(2):229-36. DOI: 10.1016/s0092-8674(00)81099-5. View

11.

Oermann C, Sockrider M, Konstan M . The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest. 1999; 115(4):1053-8. DOI: 10.1378/chest.115.4.1053. View

12.

Konstan M, Stern R, DOERSHUK C . Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr. 1994; 124(5 Pt 1):689-93. DOI: 10.1016/s0022-3476(05)81356-3. View

13.

Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M . Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax. 1995; 50(12):1246-52. PMC: 1021345. DOI: 10.1136/thx.50.12.1246. View

14.

Andersson C, Roomans G . Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J. 2000; 15(5):937-41. DOI: 10.1034/j.1399-3003.2000.15e21.x. View

15.

Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R . Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 1999; 292(1):156-63. View

16.

Konstan M, Berger M . Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol. 1997; 24(2):137-42; discussion 159-61. DOI: 10.1002/(sici)1099-0496(199708)24:2<137::aid-ppul13>3.0.co;2-3. View

17.

Konstan M, Byard P, Hoppel C, DAVIS P . Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332(13):848-54. DOI: 10.1056/NEJM199503303321303. View

18.

Southern K, Barker P, Solis A . Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2000; (3):CD002203. DOI: 10.1002/14651858.CD002203. View

19.

Sugiyama Y, Yanagisawa K, Tominaga S, Kitamura S . Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J. 1999; 14(5):1113-6. DOI: 10.1183/09031936.99.14511139. View

20.

Knowles M, Hohneker K, Zhou Z, Olsen J, Noah T, Hu P . A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med. 1995; 333(13):823-31. DOI: 10.1056/NEJM199509283331302. View